New pill targets cancer's repair system in advanced tumors

NCT ID NCT05898399

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests a new oral drug called ART6043, which blocks a DNA repair protein in cancer cells. It is given alone or with olaparib to adults with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if it is safe and can shrink or slow tumor growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínico Universitario de Valladolid

    RECRUITING

    Valladolid, Castille and León, 47003, Spain

  • Hospital San Pedro de Alcántara

    RECRUITING

    Cáceres, Extremadura, 10003, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Clínico San Cecilio

    RECRUITING

    Granada, Andalusia, 18007, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Catalonia, 08025, Spain

  • Jefferson University Hospitals - Kimmel Cancer Center

    ACTIVE_NOT_RECRUITING

    Philadelphia, Pennsylvania, 17107, United States

  • Mary Crowley Cancer Center - Clinic

    COMPLETED

    Dallas, Texas, 75251, United States

  • Memorial Sloan-Kettering Cancer Center (MSKCC)

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065-6800, United States

  • SCRI oncology partners

    COMPLETED

    Nashville, Tennessee, 37203, United States

  • South Texas Accelerated Research Therapeutics (START) - Midwest

    ACTIVE_NOT_RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Stephenson Cancer Center - Oncology

    ACTIVE_NOT_RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • The University of Texas - MD Anderson Cancer Center

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.